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Results:
The authors reported calculated PPV in each database (table 2) only for those considered assessable cases. This is misleading, because the resulted PPV in those databases with high number of non-assessable cases is overestimated. Although there are important differences in the characteristics between confirmed cases and the total number of identified cases, and most likely these differences are reflecting that non-assessable cases might not be cases, they are expected not occurring at random and might be related to other characteristics of patients or of the database can compromise the validity of identifying these cases. The "overall PPV" labeled in the table is in fact "the PPV of assessable cases". I suggest if possible to reclassify the group of non assessable cases in levels of certainty or to present the table with the PPV of assessable cases and the overall PPV including both assessable and non assessable cases (or cases with insufficient information) to provide the overall picture.
5. Results: it will be important to present the PPV among cases with prior history of AMI and among those w/o it (truly incident cases).
6. Discussion: The impact of the potential misclassification of cases have been evaluated, however, it is unclear how the "non-assessable cases" are impacting this misclassification and the implications of identifying AMI cases for further studies. Also, it should be discussed how misclassification of assessable and non assessable cases can compromise the external validity (i.e. estimation of incidence rates)
VERSION 1 -AUTHOR RESPONSE
Reviewer 1: C. Varas-Lorenzo, Director Epidemiology, RTI-HS, Barcelona, Spain
This manuscript reports the results of a validation study of random sampled (n=800) cases of potential AMI identified in three electronic health record databases from Denmark, Italy and the Netherlands within the EU-ADR project. The three databases used different disease dictionary codes (ICD9-CM, ICD-10 and IPCI). The manuscript is very well written and presents clearly the importance of validating case identification in electronic health record databases for pharmacoepidemiology research. The efforts of conducting such validation study are very much appreciated. There are some questions, however, that need clarification and should be addressed by the authors prior to its publication.
1. Methods: PPV was calculated excluding non-assessable cases. This is questionable and results can be misleading in databases where the frequency of "non-assessable cases" is high. Usually in the validation process, potential cases are classified in different levels of certainty (i.e definite, probable or possible, insufficient information, …) and PPV is calculated for each level of certainty and overall. The criteria used to classify cases as non-assessable are not described. Where they really nonassessable cases at all or they were cases with insufficient information to meet the criteria of confirmed case? Please describe the criteria used for declaring cases as "non-assessable".
Reply: Thank you very much for this comment. We defined, a priori, a case to be non-assessable if the corresponding medical records/hospitalisation charts could not provide adequate information for the clinical reviewer to be able to say whether it was an actual case of acute myocardial infarction (AMI) or not. An example of this would be a case (identified automatically by a disease code in general practitioner records) where, during manual review, the diagnosis code for AMI appears at least once in the record, but no clinical symptoms or results of laboratory examinations (e.g., ECG or cardiac enzymes) can be found further in the record. A second scenario is that of such supporting data being present, but may be contradictory. A third example would be a case where there are other related medical conditions (i.e. possible differential diagnoses for AMI) occurring within the same time frame as the AMI, but the clinical course -as described in the general practitioner records -does not allow distinction as to whether the case is indeed that of AMI or not. In this particular validation study we wanted to dichotomise cases only into "definite case" and "non-case" (i.e. we developed the algorithm in such a way that it did not consider gray areas of "possible" or "probable"); the consequence of this was that a considerable number of cases became classified as non-assessable. In order to clarify the issue on the non-assessable (as well as non-retrievable) cases and to show how they impact on the PPV, in the revised version of the manuscript we now include in the Methods section a discussion on "best-case scenario" PPV and "worst-case scenario" PPV. We now re-label the previously calculated PPVs as "best-case scenario" PPVs, where neither non-assessable nor nonretrievable cases were included in the denominator in the calculation of the PPV. We have now also re-calculated how the PPVs would be if we included both non-assessable and non-retrievable cases in the denominator; we label these PPVs as "worst-case scenario" PPVs. For Aarhus, the number of cases that would have been retrieved per code was estimated based on the % distribution of codes in the retrieved cases within the random sample. The corresponding tables have been revised accordingly.
Methods: In the identification of cases it is not clear if community deaths have been included or not.
In relation with this, please clarify why sudden cardiac of death is excluded from the computer algorithm.
Reply: Thank you for this comment. No, we did not specifically include community deaths, but deaths with myocardial infarction as reported cause (whether in-hospital or out-of-hospital) -when documented in the general practitioner"s records or in the death registry -were included. However, we used the information on death only as supporting information for the identification of a case of myocardial infarction (i.e. to determine how many of the identified cases died within the study period and also to identify any double-counting of cases). In the EU-ADR Project, we considered sudden cardiac death as a distinct event from acute myocardial infarction; thus, we did not include sudden cardiac death in the case definition and in the subsequent algorithm.
3. Results: The authors mentioned that 52 potential cases in Aarhus could not be accessed because logistical reasons. This number seems high especially in relatively short time study period. Which were these logistical reasons? Because the final PPV is 100% (w/o taking into account the number of charts that were not retrieved) one can speculate that access to hospital charts might be related to facilities with better coding practices or other high quality aspects, resulting in a 100% PPV. Could you please comment on this? Can you provide additional information on the non-retrieval charts?
Reply: Thank you for this important comment. The 52 potential cases in Aarhus that could not be retrieved were from hospitals where Aarhus did not have prior institutional agreement that allowed access to medical charts. We have no reason to believe that these said hospitals would have less accurate or less reliable coding practices, or inferior quality of data. Unfortunately, because of time constraints there was no opportunity to re-sample and replace these 52 cases. As mentioned in the response to comment #1, we have re-calculated the PPVs in the revised version of the manuscript to take into account the effect of both non-retrievable and non-assessable cases.
Results:
The authors reported calculated PPV in each database (table 2) only for those considered assessable cases. This is misleading, because the resulted PPV in those databases with high number of non-assessable cases is overestimated. Although there are important differences in the characteristics between confirmed cases and the total number of identified cases, and most likely these differences are reflecting that non-assessable cases might not be cases, they are expected not occurring at random and might be related to other characteristics of patients or of the database can compromise the validity of identifying these cases. The "overall PPV" labeled in the table is in fact "the PPV of assessable cases". I suggest if possible to re-classify the group of non assessable cases in levels of certainty or to present the table with the PPV of assessable cases and the overall PPV including both assessable and non assessable cases (or cases with insufficient information) to provide the overall picture.
Reply: As mentioned in the response to comment #1, we have re-calculated the PPVs in the revised version of the manuscript. We now re-label the previously calculated "overall PPV" as "best-case scenario" PPV, where neither non-assessable nor non-retrievable cases were included in the denominator in the calculation of the PPV. We have now also re-calculated how the PPVs would be if we included both non-assessable and non-retrievable cases in the denominator; we label these PPVs as "worst-case scenario" PPVs. The corresponding tables have been revised accordingly.
Reply: Thank you for this comment. Indeed, it would be important to show this. However, in our study all cases validated were truly incident cases (as determined in the answer to the questionnaire item "Was the myocardial infarction referred to as "old myocardial infarction" or "history of myocardial infarction?").
Reply: Thank you for this valuable comment. As mentioned in the response to comment #1, we have re-calculated the PPVs in the revised version of the manuscript to include how the PPVs would be if we included both non-assessable and non-retrievable cases in the denominator; we label these PPVs as "worst-case scenario" PPVs. We further state in the Discussion how potentially large the impact of these missing cases would have on the PPVs and reiterate the need for adequate case retrieval in outcome validation studies, advocating re-sampling of cases when necessary and taking into account non-assessable (and non-retrievable) cases in the analyses. As also mentioned in the response to comment #1, we made the decision in this particular study to dichotomise AMI cases only into "definite case" and "non-case" (i.e. we developed the algorithm in such a way that it did not consider gray areas of "possible" or "probable"). It is likely that most of the cases we deemed non-assessable would have been considerable "probable" or "possible" if we had adopted such an algorithm. Having said that, we believe that incidence rates obtained using these definitions of AMI (even with the non-assessable cases) remain valid as long as it is clear which definitions were used to derive such rates.
Reviewer 2: Steen Z. Abildstrøm, MD PhD, Consultant Cardiologist , Dpt of Cardiology, Bispebjerg Hospital, Copenhagen, Denmark 1. The cohort is very complex, and you probably need to find the earlier papers to fully understand the process. Did all registries cover the same period? Was follow-up time similar in the registries, and was it truncated at e.g. 2 year or maximised with censoring. Was it only a patients first AMI admission or could it be a recurrent event.
Reply: Thank you for this comment. In order to clarify how the study cohort was assembled, we now include in the revised a version of the manuscript a section on "Cohort definition and follow-up time." To harmonise follow-up definitions across databases, we defined the eligibility period for each patient as starting on the date of registration in the database and ending on the date the patient transfers out of the system, with the last supply of data, occurrence of AMI (as described in the subsequent section on "Identification of acute myocardial infarction"), or on the patient"s death, whichever is earlier. In order to be included in the study cohort, subjects had to have at least one year of continuous and valid data. In addition, we now provide in Appendix 1 (available online as supplementary file) a table of database characteristics of the entire EU-ADR network. The table includes the calendar years covered in each database for this particular study.
Regarding AMI, we only considered incident events. Thank you for pointing out that this was not explicit in the manuscript. In the section on "Identification of acute myocardial infarction," we added the statement "We only considered the first occurrence (first diagnosis of AMI) in each patient."
2. The use of medication is not defined: was exposure claiming a prescription once in the period or based on free-text mining, and how long was the individuals followed with regard to developing a later event.
Reply: Thank you for this valuable comment. In the revised version of the manuscript we now include in the Methods section, under the subheading "Statistical analyses -b. Effect of outcome misclassification on AMI risk estimation during drug use" a description of how drug exposure was assessed:
"Drug prescription and/or dispensing data were used to estimate incidence rate of AMI during drug exposure. Drug prescriptions and dispensings are locally coded in each database (see Appendix 1), but these codes are linked to the Anatomical Therapeutic Chemical Classification (ATC, http://www.whocc.no/atc_ddd_index/) system, which is used as the common drug coding system in the EU-ADR network. Overlapping treatment episodes with the same drug (same ATC code) are combined into a single episode of drug use that starts when the first prescription begins and stops when the last prescription ends. When a patient uses more than one drug at a time, the corresponding person-time is labeled accordingly. Using individual data on start date and end date of prescription or dispensing, those periods during which an individual is included in the study, but is not using any drug, are marked as unexposed. Events are then assigned to the episodes (drug use/nonuse) in which they occurred. The duration covered by each prescription or dispensing is estimated, within each database, according to the legend duration (if dosing regimen is available), or is otherwise based on the defined daily dose (DDD). We estimated the incidence rate of AMI during current use of six reference drugs…"
3. The IRR associated with rosiglitaszone dropped from 2.4 (1.6-3.7) to 1.6 (0.8-3.4). This change is described as 'small', 'not significantly, and 'little impact'. The use of administrative data in science calls for the highest precision and cautious interpretation.
Reply: Thank you for this valuable comment. We assume the reviewer is referring to the following statements in the last paragraph of the Results section:
"In general, although the number of AMI cases identified using all eligible codes ("AMI") was greater compared to the case definitions based on code with ≥50% PPV or ≥75% PPV (i.e. AMI50 and AMI75), there was only a small change in the resulting IRRs. For the positive control drug rosiglitazone, the IRR was 2.4 (95% CI: 1.6-3.7) with "AMI", and decreased to 1.6 (95% CI: 0.8 -3.4) with both "AMI75" and "AMI50" definitions. The same trend was observed for rofecoxib and levonorgestrel/estrogen. For the negative controls the impact of using codes with different PPVs was even less pronounced."
We agree with the reviewer that these statements can be misconstrued and we echo the sentiment that use of secondary data in science "calls for the highest precision and cautious interpretation," as is true for all data sources. To clarify that we do not intend to label as "small" and having "little impact" a change of IRR from 2.4 (1.6-3.7) to 1.6 (0.8-3.4), we have revised the above statements accordingly as follows:
"In general, although the number of AMI cases identified using all eligible codes ("AMI") was greater compared to case definitions based on code with ≥50% PPV or ≥75% PPV (i.e. "AMI50" and "AMI75"), there was only a small change in the resulting IRRs. The clear exception is the positive control drug rosiglitazone, in which the IRR of 2.44 (95% CI: 1.62 to 3.67) with the "AMI definition" decreased to 1.62 (95% CI: 0.77 to 3.41) with "AMI75," the risk then becoming insignificant; the IRR remained fairly stable at 1.64 (95% CI: 0.78 to 3.45) with the "AMI50" definition. The same trend was observed for rofecoxib and levonorgestrel/estrogen: although the IRR changes corresponding to each definition were smaller compared to rosiglitazone, the risk disappeared with both "AMI75" and "AMI50" definitions. For the negative controls (where the 95% CIs all included 1) the impact of using codes with different PPVs was less pronounced."
4. Of the 200 cases from Aarhus 52 could not be found from 'logistaical reasons'. This is stated to be without risk of bias, but seems to be a limitation, and if the 52 cases were entered in the denominator PPV would drop from 100 to 74%.
Reply: Thank you for this comment. The 52 potential cases in Aarhus that could not be retrieved were from hospitals where Aarhus did not have prior institutional agreement that allowed access to medical charts. We have no reason to believe that these said hospitals would have less accurate or less reliable coding practices, or inferior quality of data. Unfortunately, because of time constraints there was no opportunity to re-sample and replace these 52 cases. In order to clarify the issue on the nonretrievable (as well as non-assessable) cases and to show how they impact on the PPV, in the revised version of the manuscript we now include a discussion on "best-case scenario" PPV and "worst-case scenario" PPV. We now re-label the previously calculated PPVs as "best-case scenario" PPVs, where neither non-assessable nor non-retrievable cases were included in the denominator in the calculation of the PPV. We have now also re-calculated how the PPVs would be if we included both non-assessable and non-retrievable cases in the denominator; we label these PPVs as "worstcase scenario" PPVs. The corresponding tables have been revised accordingly.
5. Please define EU-ADR at first mention.
Reply: In this revised version of the manuscript we now add a brief description of the EU-ADR Project in the last paragraph of Reply: Thank you for pointing this out; this was a typographical error. It should have been 93 cases confirmed by a medical specialist out of a total of 93 overall confirmed cases (100%). This has been changed accordingly.
7. The use (and hence validation) of death certificates seems to be sparse, and may be omitted from the introduction.
Reply: Thank you for this comment. Two (2) cases of acute myocardial infarction (out of 200 cases) were confirmed using the death registry in the Aarhus database system. In the revised version of this manuscript we have deleted from the Abstract the phrase "death registries" in the sentence "Validation study of cases of AMI identified from general practitioner records, hospital discharge diagnoses, and death registries…" Death registries, or death certificates, were not mentioned in the Introduction, but were mentioned in the Methods section in the context of describing the nature of the Aarhus database.
8. The Discussion usually starts with the main findings.
Reply: Thank you for this comment. This was indeed the intention in the first paragraph of the Discussion, although -as a matter of style -we chose to reiterate the context of the study results first before proceeding to summarise the main findings. In the revised version of the manuscript, the Discussion now starts directly with a statement of the main findings.
9. In the article summary limitations should be extended. The last key message seems to be a fragment: 'Codes with <50% PPV had little impact on the estimation of risk of AMI during drug use, although precision was lower when using the most specific definition of AMI.'
Reply: Thank you for this valuable comment. In the revised version of the manuscript, we have completely rewritten and extended this item, as far as can be allowed by space constraints. This particular key message now reads:
